Authors
David John McMahon, Elizabeth Bancroft, George J Burghel, Ellen Copson, Michael Hubank, Jennifer Wiggins, Katie Snape, Natalie Cook, Ian Frayling, Matthew J Murray, Alastair Greystoke, Matthew G Krebs, Sanjay Popat, Terri Patricia McVeigh, UK Circulating Biomarkers Network of Excellence and the National ctDNA Steering Committee
Published in
JCO precision oncology. Volume 10. Issue 10. Pages e2600366. Epub Oct 07, 2026.
Abstract
Modern cancer diagnostics is heavily reliant on molecular data. Next-generation sequencing using liquid biopsy (LB) is primarily focused on identifying predictive and prognostic biomarkers to guide systemic therapy decision making. However, additional findings including genomic variants of possible or probable germline origin are detected in a significant minority of patients (3%-18%), with significant implications for patients and their families. Pretest information provision regarding both the purpose and potential benefits of the test and additional findings on LB varies in clinical practice, with little guidance for clinicians regarding the degree of detail required regarding possible additional findings. LB requires explicit disclosure of these aspects. Implementing a standardized, context-dependent approach to this discussion, with nationally standardized information provision tools, should be prioritized to enable patient-centered decision making regarding LB, without prioritizing the incidentalome over the primary purpose of the test-refining and optimizing treatment options.
PMID:
42842845
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0